James Peyer - Feb 3, 2021 Form 3/A - Amendment Insider Report for Sensei Biotherapeutics, Inc. (SNSE)

Role
Director, 10%+ Owner
Signature
/s/ Sarah Field, Attorney-in-Fact
Stock symbol
SNSE
Transactions as of
Feb 3, 2021
Transactions value $
$0
Form type
3/A - Amendment
Date filed
8/1/2022, 05:40 PM
Date Of Original Report
Feb 3, 2021
Next filing
Apr 21, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SNSE Common Stock 2.28M Feb 3, 2021 See footnote F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SNSE Series AA Preferred Convertible Stock Feb 3, 2021 Common Stock 111M See footnote F1, F2
holding SNSE Series BB Preferred Convertible Stock Feb 3, 2021 Common Stock 4.82M See footnote F1, F2
holding SNSE Stock Option (right to buy) Feb 3, 2021 Common Stock 19.5K $3.22 See footnote F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Dr. Peyer disclaims beneficial ownership of such shares.
F2 Each share of the Series AA Preferred Stock and Series BB Preferred Stock is convertible, at any time, at the holder's election, into 0.0208333 shares of the Issuer's common stock. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series AA Preferred Stock and Series BB Preferred Stock will automatically convert into 0.0208333 shares of the Issuer's common stock. The Series AA Preferred Stock and Series BB Preferred Stock haves no expiration date. Dr. Peyer disclaims beneficial ownership of such shares.
F3 The shares subject to the option vest monthly over twenty-four (24) months from the vesting commencement date, March 31, 2020, subject to the continuous service of James Peyer on the Issuer's Board of Directors. Dr. Peyer is the Chief Executive Officer of Cambrian and disclaims beneficial ownership of such shares.
F4 Amendment filed solely to correct the number of shares owned.